VSTM — Verastem, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1526119 ·
Last close
$7.41
Market Cap
$933.77M
52W High
$10.82
52W Low
$3.43
ADV30
4,823,134
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 24,012,000 | 20,067,000 | -75,224,000 | -74,723,000 | 229,637,000 | 172,801,000 | 219,536,000 |
| Jun 2026 | 40,078,000 | 36,037,000 | -32,710,000 | -34,673,000 | 206,511,000 | 136,353,000 | 156,525,000 |
| Mar 2026 | 18,671,000 | 15,620,000 | -44,897,000 | -36,591,000 | 227,808,000 | 165,551,000 | 146,031,000 |
| Dec 2025 | 17,535,000 | 14,643,000 | -41,475,000 | -32,916,000 | 246,442,000 | 204,990,000 | 189,245,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-162,195,000
Investing CF
$-9,389,000
Financing CF
$143,615,000
CapEx
$-1,345,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.78
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,236,262,000
Inventory
$2,396,000
Receivables
$29,074,000
ST Investments
$16,127,000
EBIT TTM
$-200,406,000
Pretax Income TTM
$-201,882,000
Interest Exp TTM
$1,476,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$100,296,000
EBITDA
$-193,170,000
Free Cash Flow
$-92,652,496
Enterprise Value
$1,015,544,512
Total Cash
$172,800,992
Total Debt
$128,561,000
Shares Out
126,014,804
Trailing EPS
$-1.84
Book Value
$0.11
ROE
-471.2%
ROA
-59.8%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 30,914,000 | -170,129,000 | -209,471,000 | 246,442,000 | 189,245,000 | 57,197,000 | -137,509,000 |
| Dec 2024 | 10,000,000 | -114,956,000 | -130,637,000 | 101,538,000 | 130,431,000 | -28,893,000 | -104,771,000 |
| Dec 2023 | 0 | -92,084,000 | -87,367,000 | 149,718,000 | 92,344,000 | 57,374,000 | -86,460,000 |
| Dec 2022 | 2,596,000 | -72,937,000 | -73,812,000 | 95,050,000 | 47,659,000 | 47,391,000 | -63,673,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$86,566,000
NetIncome TTM
$-202,698,000
OpCashFlow TTM
—
Assets (Latest)
$206,511,000
Forward EPS
$-1.22
Max Pain — expiry 2027-01-15
max pain strike: $6.00 · spot: $6.87 · call oi: 6,210 · put oi: 1,460
Expected Move to 2027-01-15:
±$2.12
(30.93%) —
implied range
$4.74 –
$8.99
· ATM straddle on $7.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LTGO | Latigo Biotherapeutics, Inc. | $912.28M | $13.76 | — |
| MLTX | MoonLake Immunotherapeutics | $957.45M | $11.25 | — |
| SPTX | Seaport Therapeutics, Inc. | $972.65M | $18.17 | — |
| JBIO | Jade Biosciences, Inc. | $979.40M | $15.40 | — |
| SVRA | Savara Inc | $988.39M | $4.48 | — |
News headlines (Yahoo Finance, 1h cache)
Verastem Oncology Announces Late-Breaking Oral Presentation of VS-7375 Lung Cancer Data at IASLC/ASCO 2026 North America Conference on Lung Cancer
2026-11-18 14:00 · Yahoo
Verastem Weighs Partnership or Solo Launch as Cancer Drug Trials Advance
2026-11-16 19:13 · Yahoo
Verastem Stock In Focus After Earnings Update And New Financing Plans
2026-11-13 02:14 · Yahoo
Verastem Bets on Higher Cancer Drug Dose as It Maps Potential Approval Path
2026-11-11 14:13 · Yahoo
Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans
2026-11-10 07:12 · Yahoo
What Verastem (VSTM) Said on Its Q3 Earnings Call
2026-11-07 00:14 · Yahoo
Verastem (VSTM) Q3 2026 Earnings Call Transcript
2026-11-06 23:50 · Yahoo
Verastem (VSTM) Wins FDA Priority Review, Is The Stock Cheap Or Priced For More?
2026-11-06 21:12 · Yahoo
Verastem, Inc. Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
Verastem Inc (VSTM) Q3 2026 Earnings Call Highlights: Avmapki Revenue Surges 114% as VS-7375 ...
2026-11-06 09:18 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.